u/arne_ilunga

identity, quantity, stability — three separate questions

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Do you have the publication or the press release?

Push back: an open-label extension tells you about the people who stayed. That is a different question.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.

What jurisdiction are you asking about? The answer has changed in several.

the appendix is where the interesting tables live

preclinical enthusiasm is not clinical evidence

Adding the standing caveat — research material is not approved for human use, wherever you are.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

Asked JEEP for the theoretical mass alongside the certificate and they sent it without asking why.

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

the appendix is where the interesting tables live

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

read the endpoint before you read the headline

check who the comparator was before you compare anything

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

SURPASS is the diabetes programme and reports glycaemic endpoints

Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.

the tendon claims are the most repeated and the least evidenced

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Read a press release and the publication three months apart. The hedging in the second one was substantial.

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.